Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial - Concepedia

Concepedia

Publication | Open Access

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

DOI Full Paper Access

42

Citations

16

References

2024

Year

Marcin Dzienis, Juan Cundom, Christian Sebastian Fuentes, Anna Spreafico, Melanie Nordlinger, A.V. Pastor, Erin R. Alesi, A. Neki, Andrea S. Fung, Iane Pinto Figueiredo Lima,

Journal of Clinical Oncology

Abstract

Pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity and a manageable safety profile in first-line R/M HNSCC, suggesting this combination may be an alternative option for this patient population.

References

	Year	Citations

Page 1